Latest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
MAGELLAN trial passes "proof-of-principle" test
Posted Apr 06, 2011
at 09:35 AM, EDT
by Steven Rourke
Despite important bleeding complications, in the MAGELLAN trial rivaroxaban showed a 20% reduction in DVT and PE compared with enoxaparin after five weeks of extended prophylaxis, another advance in the battle against pulmonary embolism.
See:
MAGELLAN: Rivaroxaban prevents VTE in medical patients, but bleeding an issue
Previous posts
Should we prescribe novel anticoagulants or warfarin as first line agents for stroke prevention in AF?
4 Comments |
Posted May 06, 2012
at 01:25 PM, EDT by Samuel
at 01:25 PM, EDT by Samuel
Recent PE thrombolysis trials: MAPPET, MOPETT, and MUPPET, with Dr Stavros Konstantinides
No comments |
Posted Apr 27, 2012
at 11:55 AM, EDT by Samuel
at 11:55 AM, EDT by Samuel
The US Postal Service promotes heart health
No comments |
Posted Apr 20, 2012
at 01:50 PM, EDT by Samuel
at 01:50 PM, EDT by Samuel
Thrombolysis in acute pulmonary embolism: An update with Dr Stavros Konstantinides
No comments |
Posted Apr 04, 2012
at 03:08 PM, EDT by Samuel
at 03:08 PM, EDT by Samuel
Einstein PE: Rivaroxaban shines as viable monotherapy for pulmonary embolism
1 Comments |
Posted Mar 26, 2012
at 10:25 AM, EDT by Samuel
at 10:25 AM, EDT by Samuel
Also from theheart.org
Blogs I read
Who's Talking
Samuel Z Goldhaber, MD
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA
Professor of Medicine
Harvard Medical School
Director, Venous Thromboembolism Research Group
Co-Director, Anticoagulation Management Service
Cardiovascular Division
Brigham and Women's Hospital
Boston, MA















Comments